CURRICULUM VITAE

NANCY J. CHRISTMAS, M.D.

NANCY J. CHRISTMAS, M.D.

Colorado Retina Associates

MEDICAL LICENSE: CO: 44428 Expiration Date: 4/30/2021

NPI: 1619927456

GCP TRAINING: CITI Expiration: 11/28/2020

BOARD CERTIFICATIONS: Diplomate, American Board of Ophthalmology since 2000

WORK POSITIONS:

Vitreoretinal Specialist and Surgeon
Colorado Retina Associates (formerly Retinal Alliance), Denver, CO June 2006-present

Vitreoretinal specialist and surgeon
The Retina Group of Washington, Washington DC area
August 2001 -April 2006

EDUCATIONAL BACKGROUND

1990-1995 YALE UNIVERSITY SCHOOL OF MEDICINE
New Haven, CT
Doctor of Medicine, May 1995
Thesis: Treatment of full-thickness retinal holes with autologous serum in an experimental model

Outside Electives:
Primary Care, Indian Health Service, Navajo area, Winslow, AZ
Rural Medicine in Latin America, Harvard Medical School/Guatemala

1986-1990 WELLESLEY COLLEGE
Wellesley, MA
Bachelor of Arts, Psychobiology
Magna cum laude

POSTGRADUATE TRAINING:

1999-2001 UNIVERSITY OF IOWA HOSPITALS AND CLINICS
Iowa City, IA
Vitreoretinal Fellowship

1996-1999 BASCOM PALMER EYE INSTITUTE, UNIVERSITY OF MIAMI
Miami, FL
Ophthalmology Residency

1995-1996 DEACONESS HOSPITAL, HARVARD MEDICAL SCHOOL
Boston, MA
Internal Medicine Internship

ADDITIONAL LICENSURE:

Government of the District of Columbia #MD 33042
State of Iowa #32982
State of Maryland #D0057836
State of Virginia #0101231237

HONORS AND AWARDS:

2015 Best Doctors, Denver Business Journal
2014 Best Doctors, Denver Business Journal
AMA-WPC Physician Mentor Recognition Program
2008 AMA-WPC Physician Mentor Recognition Program
2000 AOS ᵂKnapp Fund Fellowship
1999 Heed Foundation Fellowship
1994 Association for Research in Vision and Ophthalmology/ Retina Research Foundation/Lawrence Travel Fellowship
1991 Yale University School of Medicine Summer Research Fellowship
1990 Durant Scholar
1989 Service Opportunity Stipend
1987 Freshman Distinction

PROFESSIONAL SOCIETY MEMBERSHIPS:

2012-present Club Vit
2007-present Denver Medical Society

2006-present Colorado Society of Physicians and Surgeons
2005-2008 American Medical Association

2009-present	Women in Retina, Mentorship Program Chair at WIO (2013, 2014, 2015)
2003-present	American Society of Retina Specialists
2002-2006	DC Metropolitan Ophthalmological Society
2002-2006	Northern Virginia Ophthalmological Society
2000-present	Women in Ophthalmology, 2011-present Board of Directors
1999-2001	Iowa Society of Ophthalmology
1998-present	American Academy of Ophthalmology
1994-2005	Association for Research in Vision and Ophthalmology
1997-1999	Florida Society of Ophthalmology
1996-1999	Miami Ophthalmological Society
1991-1995	American Medical Women's Association

HOSPITAL APPOINTMENTS:

2011-present	Red Rocks Surgery Center
2009-2011	Lincoln Surgery Center
2007-present	Harvard Park Surgery Center
2006•present	Exempla St. Joseph Hospital
2006-2009	Littleton Adventist Hospital
2006-present	Lowry Surgery Center
2006-2009	The Medical Center of Aurora
2006-present	Porter Adventist Hospital
2006-2013	Presbyterian-St. Luke's Medical Center, Denver, CO
2006-2010	Skyridge Medical Center
2001-2006	Friendship Surgery Center, Chevy Chase, MD
2001-2006	Georgetown University Medical Center, Washington, DC
2001-2006	[nova Fairfax Hospital, Fairfax, VA

2001-2006 Washington Hospital Center, Washington, DC 2001-2004 Loudoun Hospital, Loudoun, VA

MANUSCRIPT RE'nEWER:

2003-present	Ophthalmology
2003-present	Ophthalmic Surgery and Lasers

RESEARCH EXPERIENCE: Clinical Trials

SEATTLE (Acucela) Protocol number: 4429-202, Principal Investigator Title: A Phase 2b/3 multicenter, randomized, double-masked, dose ranging study comparing the efficacy and safety of emixustat HCL (ACU-4429) with placebo for the treatment of geographic atrophy associated with dry age-related macular degeneration.

STOP-Uveitis Protocol number: ML28522- Sub-Investigator Title: Study of the safety, tolerability and bioactivity of tocilizumab on patients with noninfectious uveitis 2012-present

ForseeHome (EMMES)- Sub-investigator, Title: Home Vision Monitoring in AREDS2 for Progression to Neovascular AMD using the ForseeHome Device

AREDS2 (EMMES)- Sub-investigator, Title: Age-Related Eye Disease Study 2 (AREDS2): A Multicenter, randomized trial of lutein, zeaxanthin and omega-3 long-chain polyunsaturated fatty acids (docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in age-related macular degeneration

BAM (GSK)- Sub-investigator, Title: A Phase 2, Multicenter, Randomized, Double-Masked* Placebocontrolled, Parallel-group Study to Investigate the Safety, Tolerability, Efficacy, Pharmokinetics and Pharmacodynamics of GSK933776 in Adult Patients with Geographic Atrophy Secondary to AgeRelated Macular Degeneration
2012-2016

MD71 10852 (GSK)-Sub-investigator, Title: A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration

VISTA (Regeneron)-Sub-investigator, Title: A Double-Masked, Randomized, Active-Control, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with
Diabetic Macular Edema
2011-2015

VIEW (Regeneron) Protocol: YGTF-OD-0605, Sub-investigator, Title: A Randomized, DoubleMasked, Active Controlled Phase ill Study of the Efficacy, Safety and Tolerability of Repeated Doses of Intravitreal YEGF Trap with Neovascular Age-Related Macular Degeneration

FAME (Alimera) Protocol: -C-01-1 1-008, Sub-Investigator, Title: An Open Label, Multicenter Extension Study of the Safety and Utility of the Ne Inserter of ILUVIEN (Fluocinolone Acetonide Intravitreal Insert) O. 19mg and the Safety of ILUVIEN in Subjects Diabetic Macular Edema

RISE (Genentech) Sub-Investigator, Protocol: FVF4168g A Phase 111t Double-Masked, Multicenter, Randomized , Sham-Controlled Study for Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus

HARBOR (Genentech): Sub-Investigator, Protocol:FVF4579G- Title: A Phase Ill, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5mg and 2.0 mg Ranibizumab Administered Monthly or on an as-needed Basis (PRN) in Patients with Subfoveal Neovascular Age„Related Macular Degeneration

SHORE (Genentech) Protocol: FVF4967G-Title: A Multicenter Randomized Study Evaluating Dosing

Regimens for Treatment Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion

FAME (Alimera)- Sub-Investigator, Title: A Randomized, Double-Masked, Parallel Group, Multicenter, Dose-Finding Comparison of the Safety and Efficacy of ASI-OO IA 0.5 ug/day and ASI001B 0.2 ug/day Fluocinolone Acetonide Intravitreal Inserts to Sham injection in Subjects with

Diabetic Macular Edema

2007-2010

DENALI (Novartis)-Sub-Investigator, Title: A 24 month Randomized, Double-Masked, Controlled,

Mul ticenter, Phase Study Assessing Safety and Efficacy of Verteporfin (Visudyne) Photodynamic Therapy Administered in Conjunction with Ranibizumab (Lucentis) versus Ranibizumab (Lucentis) Monotherapy in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration 2007-2010

BRAVO (Genentech)-Sub-lnvestigator, FVF4 1 65g, Title: A Phase Il Multicenter, Randomized Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary 1 Branch Retinal Vein Occlusion 2008-2011

CRUISE (Genentech)-Sub-lnvestigator, FYF4166g Title: A Phase Ill Multicenter, Randomized Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary 1 Central Retinal Vein Occlusion 2008-2011

FOVISTA (Ophthotech)-Protocol: OPH-1003, Sub-Investigator, Title: A Phase 3, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of FOVISTA^{TM} (ANTI-PEGYLATED APTAMER) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration

2014-present

FORSIGHT-Sub-lnvestigator, Title: A Prospective, Multi-Center, Randomized, Controlled Clinical Trial Designed to Evaluate the Safety and Preliminary Efficacy ofV404PDS in Chronic Noninfectious

Uveitis

20140015

ORA (Aerpio Therapeutics) Sub-Investigator, Title: A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB9778 Administered for 3 months, as Monotherapy or Adjunctive to Ranibizumab, In Subjects with Diabetic Macular Edema

2014-2015

TOGA (University of Virginia) Sub-Investigator, Title: A Randomized, Double-Masked, Placebo Controlled Study Evaluating ORACEA in Subjects with Geographic Atrophy Secondary to NonExudative Age-Related Macular Degeneration
2014-present
ORBIT (Thrombogenics) Sub-investigator, Title: Ocriplasmin Research to Better Inform 2014-present

EYEGUARD (XOMA) Sub-Investigator, Title: A Randomized, Double-Masked, Placebo Controlled
Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-Infectious Intermediate. Posterior, or Pan-Uveitis
2012-2015

EYEGUARD (XOMA) Sub-Investigator A Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treab-nent of Subjects with Non-Infectious intermediate, posterior, or pan-uveitis currently controlled with systemic treatment
2012-2015

SAKURA (Santen, Inc) Protocol: DE-109, Sub-Investigator, Title: A Phase 111, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal
Injections of DE-109 (three doses) for the Treatment of Active, Non-infectious Uveitis of The Posterior Segment of the Eye
2012-present

OPTINA (Ampio Pharmaceuticals) Sub-Investigator, Title: A Randomized, Placebo-Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina^{TN} in

OCULOS: (Ohr Pharmaceuticals) Protocol: OHR-002, Sub-investigator, Title: A Phase 2 study of the
Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration
2013-2015

EMERGE (ICONIC): Protocol: IT-002, Principal Investigator, Title: A Phase Il, Randomized, Double-Masked, Multicenter, Active-Controlled Study Evaluating the Safety of Repeated Intravitreal injections of hL-con1 administered as monotherapy or in combination with ranibizumab compared to ranibizumab monotherapy. 2015-2016

XCOVERY: (Tyrogenex) Protocol: X82-OPH-201, Sub-investigator, Title: A Randomized, DoubleMasked, Placebo-Control[ed, Dose-Finding, Non-Inferiority Study of X-82 plus prn Eylea@ monotherapy in Neovascular AMD 2015-2018

SPECTRI (LAMPA) (Genentech-Roche) Sub-Investigator, Title: A Phase ill, Multicenter, Randomized,
Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
2015-2017

NEUROTECH: (Neurotech) Protocol: NT-503-3-AMD-001), Sub-investigator, Title: A Multi-Center, Two-Stage, Open-Label Phase I and Randomized, Active Controlled, Masked Phase Il Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared with Eyelea@ for the Treatment of Recurrent Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) 2015-2016

LADDER (Genentech) Protocol: GX28228, Sub-Investigator, Title: Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration 2015-present

VIDI (ASTELLAS): Protocol: 8232-CL-OOI, Sub-investigator, Title: A Phase Il, Double-Masked, Randomized, Active-Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing
Central Retinal Thickness in Subjects with Diabetic Macular Edema 2015-2016

HAWK (Alcon): Protocol RTH258-C001, Sub-Investigator, Title: A Two-year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Afibercept in Subjects with Neovascular Age-Related Macular Degeneration 2015-present

CAPELLA (Regeneron) Protocol: R2176-3-AMD-1417, Sub-investigator, Title: A Phase Il, Double
Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176—3 in Patients with Neovascular Age-Related Macular Degeneration 2015-2017

CEDAR (Allergan): Protocol: AGN-150998, Sub-Investigator, Title: A Multicenter, Double-Masked, Randomized 100-week, Parallel-Groupa Active-Controlled Study to Evaluate the Safety and Efficacy of Abicipar in Treatment-Naive patients with Neovascular AMD. 2015-present

VAPOR (Santen) Protocol: 35-002: Sub-Investigator, Title: A Multicenter, Randomized, Open Label, Phase [la Study Assessing the Efficacy, Safety and Duration of Effect on Intravitreal Injections of DE-120 (a VEGF and PDGF Receptor Inhibitor) as Monotherapy and with a Single Eyehea@ Injection in Subjects with Treatment-Naive Exudative Age-Related Macular Degeneration.

2015-2017

ALDEYRA (Aldeyra) Protocol: NS2-02, Sub-investigator, Title: A Phase 2, Randomized, Investigator-Masked, Comparator Controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients with Anterior Uveitis
2015-2016

AVENUE (Roche) Protocol: BP29647, Sub-investigator, Title: A MultiplæCenter, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate The Safety, Tolerability, Pharmacokinetics, And Efficacy of R06867461
Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to AgeRelated Macular Degeneration 2015-2017

PROXIMA (Genentech) Protocol: GX29633, Sub-Investigator, Title: A Multicenter, Prospective Epidemiologic Study of the Progression of Geographic Atrophy Secondary to Age-Related Macular
Degeneration 2015-2018

LHA510 (Alcon/Novartis) Protocol: LHA510-2201, Sub-investigator, Title: A Randomized, Double-Masked* Vehicle-Controlled, Proof-of-Concept Study for Topically Delivered LHA510 as a Maintenance Therapy in Patients with Wet Age-Related Macular Degeneration. 2015-2017

VISTA (Regeneron) Protocol: VGFT-OD-1009, Sub-Investigator, Title: A Double-Masked, Randomized, Active-Control, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration ofVEGF Trap-Eye in Patients with Diabetic Macular Degeneration
2011-2015

AURA (Aura Biosciences) Protocol: AU-011-201, Sub-Investigator, Title: A Prospective, Randomized, Multi-Center, Masked Clinical Trial Designed to Evaluate Two Doses of LightActivated AU-OII for the Treatment of Subjects with Small to Medium (1.5»4.0 mm thickness) Primary Uveal Melanoma
2016-2018

PANORAMA (Regeneron) Protocol: VGFT-E-1412, Sub-Investigator, Title: A Phase 3, DoubÆe-Masked, Randomized Study of the Efficacy and Safety of Intravitrea] Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy
2015 - present

EXPOSURE (Genentech) Protocol: GX29455, Sub-Investigator, Title: A Phase II, Multicenter, Randomized, Single-Masked, sham injection - Study of lampalizumab Intrevitreal Injections administered to patients with Geographic atrophy, 2014-2017

EYEGATE (Eyegate) Protocol: EGP-437-006, Sub-Investigator, A Prospective, Multi-Center, Randomized, Double-Masked, Positive Controlled, Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared

to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients with Non-Infectious Anterior Segment Uveitis 2016-present

ABICIPAR DME Protocol: 1771-201-008, Sub-Investigator, A multicenter, open-label, single-arm study to evaluate abicipar for safety and treatment effect in patients with neovascular age-related macular degeneration (AMD) 2015-2016

AERPIO/TIME2B: Sub-Investigator, Phase 2 Double-masked, Placebo-Controlled Study To Assess The Safety And Efficacy Of Subcutaneously Administered AKB-9778 15mg Once Daily Or 15mg Twice Daily For 12 Months In Patients With Moderate To Severe Non-Proliferative Diabetic Retinopathy 2017-2018

OLEI: Sub-Investigator, A Phase II, Multicenter, Randomized, Single-Masked, sham injection - Study of lampalizumab Intrevitreal Injections administered to patients with Geographic atrophy who have completed prior Lampa Studies, 2013-2017

STAIRWAY: Sub-Investigator**,** This is a Phase II, multicenter, randomized, active comparator-controlled, subject and outcomeassessor masked, parallel group, 52-week study to investigate the efficacy, safety, and pharmacokinetics of RO6867461 administered at 12- and 16-week intervals in treatment-naive patients with nAMD 2016-2017

TLC399A2002: Sub-Investigator, A Phase Trial of TLC399 (ProDex) in Subjects with Macular Edema due to Retinal Vein Occlusion (RVO): A Double-masked, Randomized Trial to Evaluate Efficacy and Tolerability 2016-2018

HAWK Extension (Alcon): Protocol RTH258-C001, Sub-Investigator, Title: A Two-year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Afibercept in Subjects with Neovascular Age-Related Macular Degeneration who participated in Hawk 1. 2017-2018

BOULEVARD: BP30099 Sub-Investigator, a multiple-center, multiple-dose, randomized, active comparator−controlled, double-masked, three parallel group, 36-week study in patients with CI-DME 2016-2017

IT-003: Iconic Sub-Investigator, A Phase 1, Open-label, Multicenter Study Evaluating the Safety and Tolerability, Biologic Activity, Pharmacodynamics, and Pharmacokinetics of Single and Repeated Escalating Intravitreal Doses of ICON-I in Patients with Uveal Melanoma Who are Planned to Undergo Enucleation or Brachytherapy 2016-2017

SAPPHIRE: CLS1003-30, Sub-Investigator, A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal aflibercept in subjects with retinal vein occlusion 2016-present

GILEAD: Sub-Investigator, A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects with Active Noninfectious Uveitis 2018 – present

OPT-302: Sub-Investigator, A dose-ranging study of intravitreal OPT-302 in combination with Ranibizumab in participants with wet AMD 2018 – present

OPH2003B: Sub-Investigator, A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Subjects with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration 2018 – present

OPH2007: Sub-Investigator, A phase 2A open label to assess the safety of Zimura (Anti-C5) administered in combination with Lucentis 0.5 mg in NVAMD 2018-present

2018- Present: GR40549: Sub-Investigator, A Multicenter, open-label extension stud to evaluate the long-term safety and tolerability of the Port Delivery System with Ranibizumab in patients with Neovascular Age-related macular denegation

2018- Present: GR40548: Sub-Investigator, A Phase III, multicenter, randomized, visual assessor-masked active-comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration

2018- Present: KHB-1801, Sub-investigator, A Multicenter, double-masked, randomized dose-ranging trial to evaluate the efficacy and safety of conbercept intravitreal injection in subjects with Neovascular age-related macular degeneration

2018- present: CRTH258AUS04, Sub-Investigator, A Multicenter, randomized, double-masked Phase 3a study to assess safety and efficacy of brolucizumab 6 mg q 4 weeks compared to aflibcercept 2 mg q4 weeks in patients with neovascular age-related macular degeneration (nAMD) with persistent retinal fluid (MERLIN)

2018-Present: 010906IN, Sub-Investigator, Lumina: A Phase III, multicenter, sham-controlled, randomized, double-masked study assessing the efficacy and safety of intravitreal injections of 440 µg DE-109 for the treatment of active, non-infectious Uveitis of the Posterior Segment of the Eye

2018-Present, GR40844, Sub-investigator, A phase III, multicenter, randomized double-masked, active comparator-controlled study to evaluate the efficacy and safety of Faricimab in patients with Neovascular Age-Related Macular Degeneration (Lucerne)

2018-Present, GR40349, Sub-investigator, A Phase III, Multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of Faricimab (RO6867461) in patients with Diabetic Macular Edema (Yosemite)

2018-Present, APL2-304, **Principal Investigator**, A Phase III, multicenter, randomized, double-masked, sham-controlled study to compare the efficacy and safety of Intravitreal APL-2 Therapy with Sham injections in patients with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD)

2018-Present, ADVM-022-02, Blood specimen collection study for the measurement of Adeno-Associated Virus (AAV) Neutralizing Antibodies in subjects with Neovascular (Wet) Age-related macular degeneration

2018-Present, ADVM-022-01, An open label Phase 1 study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-related macular degeneration (Optic)

2019-present: Gemini, Sub-investigator, A genetic screening and registry study to evaluate long-term clinical outcomes and disease progression in subjects with Non-central Geographic Atrophy (GA) who are carriers of high-risk genetic complement variants associated with Dry Age-related Macular Degeneration (AMD)

2019- Present: KSI-CL-102, Sub-Investigator, A phase 2, prospective randomized, double-masked, active comparator controlled, multi-center study to investigate the efficacy and safety of repeated intravitreal administration of KSI-301 in subjects with Neovascular (Wet) Age-related macular degeneration

2019- Present: ONS-5010-002, Sub-Investigator, A Clinical effectiveness, multicenter, randomized, double-masked, controlled study of the efficacy and safety of ONS-5010 in Subjects with Subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)

2019- Present: XBR1001, Sub-Investigator, A Phase III Double-blind, parallel group, multicenter study to compare the efficacy and safety of Xlucane versus Lucentis in Patients with Neovascular Age-Related Degeneration

2019-Present, GR40973, Sub-Investigator, A Phase II, multicenter, randomized, single-masked, sham-controlled study to assess safety, tolerability, and efficacy of intravitreal injections of FHTR2163 in Patients with Geographic atrophy secondary to age-related Macular Degeneration (Gallego)

2019-Present, ALK-001, Sub-Investigator, A Phase 2/3 multicenter, randomized, double-masked, parallel-group, Placebo-controlled study to investigate the safety, Pharmacokinetics, tolerability, and efficacy of ALK-001 in Geographic Atrophy secondary to age-related macular degeneration

2019-Present, GR40550, Sub-Investigator, A Phase III, Multicenter, Randomized, visual assessor-masked, active-comparator study of the efficacy, safety, and pharmacokinetics of the Port Delivery system with Ranibizumab in patients with Diabetic Macular Edema (Pagoda)

2019- Present, VGFTe(HD)-AMD-1905, Sub-Investigator, A randomized, single-masked, active-controlled Phase 2 study of the safety, tolerability, and efficacy of repeated doses of High-dose Aflibercept in patients with Neovascular Age-Related macular degeneration. .

YALE UNIVERSITY SCHOOL OF MEDICINE, NEW HAVEN, CT

ADVISOR: PETER E. LIGGETT, M.D., Professor, Director of Retina-Vitreous Service
Department of Ophthalmology and Visual Science

1992-1995 Treatment of full-thickness retinal holes with autologous serum in an experimental model

HARVARD MEDICAL SCHOOL, MASSACHUSETTS EYE AND EAR INFIRMARY, BOSTON, MA

ADVISOR: DANIEL M. ALBERT, M.D., Director David G. Cogan Eye Pathology Laboratory
Department of Ophthalmology

1991 Effect of 1,25 dihydroxycholecalciferol on in vitro retinoblastoma cell I ines: human Rb, transgenic mouse Rb, transgenic mouse metastases

1989 Toxicity of 1.25 dihydroxycholecalciferol in a transgenic mouse model of retinoblastoma

1988 Review of cases of secondary optic nei•ve tumors at the David G. Cogan Eye Pathology Laboratory, MEEI and the Neuropatholog^{y} Laboratory, MGH

PUBLICATIONS:

Christmas NJ, Oh KT, Oh DM, Folk JC. Long-term follow-up of patients with serpiginous choroidi tis. Retina 22:550-556 , 2002

Oh KT, Christmas NJ, Folk JC. Birdshot retinochoroiditis: long-term follow-up of a chronically progressive disease. Am J Ophthalmol133:622-629,2002

Oh KT, Christmas NJ, Russell S. Late recurrence and choroidal neovasculari zation in multiple evanescent white dot syndrome. Retina 21: 182-184, 2001

Christmas NJ, VanQuill K, Murray T G, Gordon CD, Garonzik S, Tse D, Johnson TJ Schiffman J, (YBrien JM. Primary pediatric orbital implants after enucleation: Evaluation of efficacy and complications. Arch Ophthalmol 118: 503-506, 2000

Christmas NJ, Gordon CD, Tse D, Johnson T, Garonzik S, O'Brien JM. Intraorbital implants after enucleation and their complications: a 10-year review. Arch Ophthalmol 116: 1199-1203, 1998

Christmas NJ, Smiddy WE, Flynn Jr HW. Reopening of macular holes after initially successful repair.
Ophthalmology 1 05: 1835-1838, 1998

Christmas NJ. Grand Rounds. Ophthalmolou Times 22: 38-39, 1997

Christmas NJ, Smiddy WE. Vitrectomy and systemic fluconazole for treatment of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 27: 1 012-101 8, 1996

Christmas NJ, Skolik SA, Howard MA, Saito Y, Barnstable CJ, Liggett PE. Treatment of retinal breaks with autologous serum in an experimental model. Ophthalmology 1 02: 263-271 , 1995

Christmas NJ, Mead MD, Richardson EP, Albert 0M. Secondary optic nerve tumors.
Surv Ophthalmol 36: 196006, 1991

ABSTRACTS AND PRESENTATIONS:

Segal ZK, Berinstein DM, Christmas NJ, Garfinkel RA
Incidence of vitreous hemorrhage secondary to treated retinal tears with a crossed bridging vessel

- Meeting of the Association for Research in Vision and Ophthalmology Ft Lauderdale, FL (Invest Ophthalmol Vis Sci. 2004; 45:Abstract nr 5267)
- American Society of Retina Specialists Meeting, San Diego, CA, 2004

Lam LA, Osman Mii, Christmas NJ, vonFricken MA, Garfinkel RA, Berinstein DM, Murphy RP. Outcomes after combined photodynamic therapy and choroidal feeder vessel treatment for predominantly classic subfoveal ncovascularization in AMD

- American Society of Retina Specialists Meeting, San Diego, CA, 2004

Panigrahi D, Barazi MK, Osman MH, Christmas NJ, vonFricken MA, Garfinkel RA, Berinstein DM, Murphy RP.
Fluorescein and indocyanine green angiographic characteristics of retinal angiomatous proliferation lesions

- American Society of Retina Specialists Meeting, San Diego, CA, 2004

Christmas NJ.
Pars plana vitrectomy for clinically significant macular edema.
Washington Retina Symposium, Washington DC, 2003

Christmas NJ. Moderator, panel discussion.

- Symposium on ARMD: Current Approaches to Diagnosis and Treatment, Fairfax , VA, 2003

Christmas NJ. Course co-director

- Washington Hospital Center/Georgetown University Hospital Retina Symposium, Washington DC, 2002

Christmas NJ.
White spot syndromes.

- Symposium on Inflammatory Disease of the Eye and Orbit, Washington Hospital Center, Washington DC, 2002

Christmas NJ, Chung MM, Folk JC.
Ocular trauma associated with paintball pellets

- Meeting of the Association for Research in Vision and Ophthalmology

Ft. Lauderdale, FL (Invest Ophthamol Vis Sci. 2000; 14: S351 . Abstract nr 1844)

Oh KT, Christmas NJ, Folk JC. Long-term progression of birdshot chorioretinopathy

- Meeting of the Association for Research in Vision and Ophthalmology ft. Lauderdale, FL (Invest Ophthulmol Vis Sci. 2000; 14: S782. Abstract nr 4148)

Christmas NJ, VanQuill K, Murray T, Gordon C, Garonzik S, Tse 0, Johnson T, Schiffman J, O'Brien J. Primary pediatric Intraorbital implants after enucleation: evaluation of efficacy and complications

- Bascom Palmer Eye Institute 35111 Residents' Days, 1999

Christmas NJ, Gordon CD, Murray TG Tse D, Johnson T, Garonzik S, O'Brien JM.
Intraorbital implants after enuc[eation and their complications: a 10-year review

- Bascom Palmer Eye Institute 34th Annual ResidentS Days, 1998
- University of Miami/Sylvester Comprehensive Cancer Center Research Poster Session, 1998

Christmas NJ, Smiddy WE, Flynn Jr HW. Reopening of macular holes after initially successful repair

- Meeting of the Association for Research in Vision and Ophthalmology

Ft. Lauderdale, FL (Invest Ophthalmol Vis Sci. 1 998; 39: S691. Abstract nr 3173)

- Macula Society Meeting, Ft. Lauderdale, FL, 1998 (by HW Flynn Jr)
- Bascom Palmer Eye Institute 33rd Annual Residents' Days, 1997

Christmas NJ, Smiddy WE.
Vitrectomy and systemic fluconazole for treatment of endogenous fungal endophthalmitis due to Candida

- Meeting of the Association for Research in Vision and Ophthalmology, Ft. Lauderdale, FL (by WE Smiddy) (Invest Ophthalmol Vis Sci. 1995; 36: S632. Abstract nr 2900)

Christmas NJ, Sko[ik SA, Howard MA, Saito Y, Barnstable CJ, Liggett PE.
Treatment of full-thickness retinal holes with autologous serum in an experimental model

- Yale University School of Medicine, Student Research Day, 1994
- Meeting of the Association for Research in Vision and Ophthalmology, Sarasota, FL

(Invest Ophthalmol Vis Sci. 1994; 35: 1714. Abstract nr 2143)

Liggett PE, Horio B, Skolik SA, Alfaro DV, Christmas NJ, Saito Y, Mieler WF.
Use of human autologous serum in vitrectomy for full-thickness macular holes

- Meeting of the Association for Research in Vision and Ophthalmology, Sarasota FL (Invest Ophthalmol Vis Sci. 1994; 35: 1579. Abstract nr 1 502)
- Macula Society Meeting, Rancho Mirage, CA, 1994
- Retina Society Meeting, San Francisco, CA, 1993
- American Academy of Ophthalmology Meeting, Chicago, IL, 1993
- Macula Society Meeting, Naples, FL, 1993

Albert DM, Christmas NJ, Mead MD* Richardson EP. Secondary tumors of the optic nerve

- American Academy of Ophthalmology Meeting, Las Vegas, Nevada, 1988